In response to a question about the risk of removing products from reimbursement in some countries to protect the US market, Pfizer Chief Executive and PhRMA Chair Dr Albert Bourla said, "I think yes." …
Pfizer chief sets out the potential implications of 'Most Favored Nation' pricing
June 11, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
OncoSil Medical completes recruitment in TRIPP-FFX clinical trial
July 23, 2025 - - Australian Biotech -
Nyrada advances Xolatryp towards Phase 2a trial in cardioprotection
July 23, 2025 - - Australian Biotech -
Amplia Therapeutics announces $25 million placement and launches share purchase plan
July 23, 2025 - - Australian Biotech -
Percheron Therapeutics announces publication of new preclinical HMBD-002 data
July 23, 2025 - - Australian Biotech -
US leads the way on cell and gene therapy with new rapid access program
July 23, 2025 - - Latest News -
Neuraxpharm continues international expansion with launch of Australian affiliate
July 23, 2025 - - Latest News -
Companies secure certification as 'Great Places to Work'
July 23, 2025 - - Latest News